Blood clearance of nucleosomes and CTCF after surgery for colorectal cancer with peritoneal spread

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will collect blood samples around the time of cytoreductive surgery to measure circulating nucleosomes and CTCF and compare their clearance kinetics to the surgeon's CC-Score. Multiple comparison groups include patients with colorectal peritoneal metastases eligible for surgery and several non-oncological inflammatory and septic abdominal conditions. The aim is to correlate biomarker kinetics with residual tumor burden and surgical completeness using objective biological measures. The study is conducted at Hôpital Lyon Sud within the Hospices Civils de Lyon.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Common criteria:

  * Male/female over 18 years of age.
  * Weight ≥ 55 kg at inclusion.
  * Signature of a free and informed consent form.
* Specific criteria:

Group 1:

* Peritoneal metastases colorectal cancer histologically proven
* Synchronous or metachronous peritoneal metastases.
* Patients eligible for initial cytoreduction surgery.
* Non mucinous tumor (mucinous cells contingent \<30%).

Group 2:

Colorectal cancer

Group 3:

Non-oncological chronic inflammatory diseases

Group 4:

Non-oncological chronic inflammatory diseases : parietal repairs, elective sigmoidectomy for diverticulosis

Group 5:

Abdominal sepsis conditions: peritonitis due to digestive perforation in non-oncological pathology, non-perforated appendicitis, cholecystitis.

Non inclusion Criteria:

* Patient with an active cancer (excluding colorectal cancer).
* Person with a progressive autoimmune disease.

Where it's running

• Hôpital Lyon Sud
  Pierre-Bénite, France Recruiting

Study contacts

• Study coordinator: Vahan KEPENEKIAN, MD, PhD
• Email: vahan.kepenekian@chu-lyon.fr
• Phone: +33 478 862 371

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Repeated PIPAC plus standard platinum–taxane chemotherapy for advanced ovarian cancer with peritoneal spread

  This test sees if adding repeated cisplatin-based PIPAC to standard platinum–taxane chemotherapy helps women aged 18–75 with newly diagnosed FIGO IIIB–IIIC epithelial ovarian cancer and visible peritoneal carcinomatosis.

  Recruiting Phase 2 Moscow Regional Oncological Dispensary · Balashikha · NCT07514494

• Enhanced Recovery After Surgery for adults with peritoneal carcinomatosis undergoing cytoreductive surgery with or without HIPEC

  This project will try an Enhanced Recovery After Surgery (ERAS) program to see if it shortens hospital stays after cytoreductive surgery with or without HIPEC for adults with peritoneal carcinomatosis.

  Recruiting Fondazione del Piemonte per l'Oncologia · Candiolo, Turin and 1 other locations · NCT07493876

• PIPAC with Mitomycin C for unresectable peritoneal cancer

  This phase 1 study tests a breathy, pressurized chemotherapy method (PIPAC-MMC) to see if it is safe and tolerable for adults with unresectable peritoneal carcinomatosis from colorectal, appendiceal, or small bowel cancers.

  Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07487168

• Heated versus aerosolized chemotherapy delivered into the abdomen for cancer that has spread to the peritoneum

  This study will test whether heated (HIPEC) or aerosolized (PIPAC) mitomycin-based chemotherapy given into the abdomen works better and is safer for adults whose cancer has spread to the peritoneum.

  Recruiting Phase 2 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT07282834

• CEA-targeted CAR-T therapy after cytoreductive surgery for peritoneal colorectal cancer

  This trial will test whether CEA-targeted CAR-T cells delivered into the abdomen after cytoreductive surgery can help people with colorectal cancer that has spread to the peritoneum.

  Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07247396

• Adding paclitaxel into the abdominal cavity for gastric cancer that has spread to the peritoneum

  This trial will try adding paclitaxel delivered directly into the abdomen to standard IV chemotherapy for people with gastric or gastroesophageal junction cancer that has spread to the lining of the abdominal cavity to see if it slows disease growth and helps them live longer.

  Recruiting at 78 sites Phase 2/3 Eastern Cooperative Oncology Group · Irvine, California and 77 other locations · NCT07001748

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.